Oculis Holding AG [OCS] vs Regeneron [REGN] Detailed Stock Comparison

Oculis Holding AG

NASDAQ
Loading...

Regeneron

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Oculis Holding AG wins in 4 metrics, Regeneron wins in 13 metrics, with 0 ties. Regeneron appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricOculis Holding AGRegeneronBetter
P/E Ratio (TTM)63.6315.13Regeneron
Price-to-Book Ratio6.432.09Regeneron
Debt-to-Equity Ratio0.729.04Oculis Holding AG
PEG Ratio-16.23-200.46Regeneron
EV/EBITDA-10.0512.86Oculis Holding AG
Profit Margin (TTM)0.00%31.37%Regeneron
Operating Margin (TTM)-7,957.09%29.64%Regeneron
EBITDA Margin (TTM)N/A29.64%N/A
Return on Equity-83.96%15.34%Regeneron
Return on Assets (TTM)-29.71%6.66%Regeneron
Free Cash Flow (TTM)$-59.97M$3.54BRegeneron
Dividend YieldN/A0.46%N/A
1-Year Return24.65%-42.36%Oculis Holding AG
Price-to-Sales Ratio (TTM)1,203.594.47Regeneron
Enterprise Value$955.21M$57.45BRegeneron
EV/Revenue Ratio995.124.04Regeneron
Gross Profit Margin (TTM)N/A85.58%N/A
Revenue per Share (TTM)$0$133Regeneron
Earnings per Share (Diluted)$-2.91$39.66Regeneron
Beta (Stock Volatility)0.130.31Oculis Holding AG
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Oculis Holding AG vs Regeneron Stock Performance Analysis

Loading Price Chart...

Oculis Holding AG
Regeneron
Oculis Holding AG Stock Overview | Regeneron Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Oculis Holding AG5.61%5.82%7.59%-0.96%29.16%9.63%
Regeneron-2.42%4.41%4.84%8.80%2.22%-18.14%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Oculis Holding AG24.65%87.10%91.54%91.54%91.54%91.54%
Regeneron-42.36%-20.46%-2.38%13.78%1,988.02%6,243.23%

News Based Sentiment: Oculis Holding AG vs Regeneron

Oculis Holding AG

News based Sentiment: POSITIVE

The positive Phase 2 trial results for Privosegtor are a significant development for Oculis, potentially opening the door to a new treatment for acute optic neuritis. However, the 'Very High' uncertainty rating from Morningstar underscores the inherent risks associated with pharmaceutical development, creating a mixed but overall positive narrative for the month.

View Oculis Holding AG News Sentiment Analysis

Regeneron

News based Sentiment: POSITIVE

October proved to be a positive month for Regeneron, marked by key FDA approvals for Lynozyfic and Evkeeza, encouraging trial results for their obesity pipeline, and positive analyst coverage from JP Morgan and Morningstar. While the Eylea biosimilar settlement introduces a future challenge, the overall narrative points towards continued growth and potential value for investors.

View Regeneron News Sentiment Analysis

Performance & Financial Health Analysis: Oculis Holding AG vs Regeneron

MetricOCSREGN
Market Information
Market Cap i$919.54M$63.78B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i28,1201,129,150
90 Day Avg. Volume i20,6301,040,977
Last Close$18.56$585.48
52 Week Range$13.60 - $23.08$476.49 - $1,024.36
% from 52W High-19.61%-42.84%
All-Time High$23.08 (Jan 13, 2025)$1,211.20 (Aug 26, 2024)
% from All-Time High-19.58%-51.66%
Growth Metrics
Quarterly Revenue Growth0.07%0.04%
Quarterly Earnings GrowthN/A-0.03%
Financial Health
Profit Margin (TTM) i0.00%0.31%
Operating Margin (TTM) i-79.57%0.30%
Return on Equity (TTM) i-0.84%0.15%
Debt to Equity (MRQ) i0.729.04
Cash & Liquidity
Book Value per Share (MRQ)$2.73$287.55
Cash per Share (MRQ)$3.06$72.04
Operating Cash Flow (TTM) i$-70,665,524$4.74B
Levered Free Cash Flow (TTM) i$-28,741,479$2.85B
Dividends
Last 12-Month Dividend Yield iN/A0.46%
Last 12-Month Dividend iN/A$2.64

Valuation & Enterprise Metrics Analysis: Oculis Holding AG vs Regeneron

MetricOCSREGN
Price Ratios
P/E Ratio (TTM) i63.6315.13
Forward P/E i-7.8413.24
PEG Ratio i-16.23-200.46
Price to Sales (TTM) i1,203.594.47
Price to Book (MRQ) i6.432.09
Market Capitalization
Market Capitalization i$919.54M$63.78B
Enterprise Value i$955.21M$57.45B
Enterprise Value Metrics
Enterprise to Revenue i995.124.04
Enterprise to EBITDA i-10.0512.86
Risk & Other Metrics
Beta i0.130.31
Book Value per Share (MRQ) i$2.73$287.55

Financial Statements Comparison: Oculis Holding AG vs Regeneron

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)OCSREGN
Revenue/Sales i$0$3.03B
Cost of Goods Sold iN/A$464.30M
Gross Profit iN/A$2.56B
Research & Development i$18.73M$1.34B
Operating Income (EBIT) i$-26.09M$591.70M
EBITDA i$-25.30M$900.90M
Pre-Tax Income i$-31.91M$905.00M
Income Tax i$-30,153$96.30M
Net Income (Profit) i$-31.88M$808.70M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)OCSREGN
Cash & Equivalents i$80.74M$3.09B
Total Current Assets i$208.82M$17.57B
Total Current Liabilities i$45.92M$3.57B
Long-Term Debt i$904,615$2.70B
Total Shareholders Equity i$179.79M$29.39B
Retained Earnings i$-432.39M$32.38B
Property, Plant & Equipment i$2.01MN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)OCSREGN
Operating Cash Flow i$-18.69M$1.36B
Capital Expenditures i$-158,307N/A
Free Cash Flow i$-21.82M$773.60M
Debt Repayment i$-91,717N/A
Common Stock Repurchase iN/A$-1.05B

Short Interest & Institutional Ownership Analysis

MetricOCSREGN
Shares Short i10,9422.99M
Short Ratio i0.793.06
Short % of Float i0.00%0.03%
Average Daily Volume (10 Day) i28,1201,129,150
Average Daily Volume (90 Day) i20,6301,040,977
Shares Outstanding i54.86M109.62M
Float Shares i41.34M97.89M
% Held by Insiders i0.06%0.02%
% Held by Institutions i0.31%0.90%

Dividend Analysis & Yield Comparison: Oculis Holding AG vs Regeneron

MetricOCSREGN
Last 12-Month Dividend iN/A$2.64
Last 12-Month Dividend Yield iN/A0.46%
3-Year Avg Annual Dividend iN/A$0.88
3-Year Avg Dividend Yield iN/A0.14%
3-Year Total Dividends iN/A$2.64
Ex-Dividend DateN/AAug 18, 2025